STAT+: The biotech scorecard for the first quarter: 26 st...

What’s Happening

Let’s talk about Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter.

Pharmalot Pharmalot STAT Plus: 3 issues to watch in biopharma in 2026 By Ed Silverman and Elaine Chen Biotech Biotech STAT Plus: A biotech incubator in China tries to unlock innovation — alongside drugmakers worldwide By Brian Yang Politics Politics STAT Plus: Three major health care policy issues to watch in 2026 By John Wilkerson Pharma Pharma STAT Plus: With the Wegovy pill, Novo Nordisk undercuts Eli Lilly in direct-to-consumer market By Elaine Chen Health Health Best of STAT 2025 By Gary Marshall NIH begins review of thousands of delayed research proposals, funding 135 on first day By Anil Oza STAT Plus: NIH director says DEI-related grants that were restored under a court order clutched’t be renewed By Anil Oza STAT Plus: Three major health care policy issues to watch in 2026 By John Wilkerson In 2026, Kennedy’s MAHA vision gets put to the test. (plot twist fr)

Why This Matters

Health experts are weighing in on what this means for people.

This is the kind of health news that affects everyday decisions.

The Bottom Line

This story is still developing, and we’ll keep you updated as more info drops.

Sound off in the comments.